Neumora Therapeutics (NASDAQ:NMRA) Upgraded at William Blair

William Blair upgraded shares of Neumora Therapeutics (NASDAQ:NMRA) from a market perform rating to an outperform rating in a report issued on Tuesday morning, Marketbeat.com reports.

NMRA has been the subject of several other reports. Stifel Nicolaus boosted their price target on Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a report on Monday, November 17th. Leerink Partners initiated coverage on shares of Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price target on the stock. Royal Bank Of Canada upgraded Neumora Therapeutics from a “sector perform” rating to an “outperform” rating and upped their price objective for the stock from $4.00 to $7.00 in a report on Monday, December 1st. Guggenheim upgraded Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a report on Monday, October 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $8.13.

Neumora Therapeutics Price Performance

Shares of NASDAQ:NMRA opened at $3.48 on Tuesday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.85 and a current ratio of 6.85. The stock has a market cap of $581.47 million, a PE ratio of -2.37 and a beta of 3.20. Neumora Therapeutics has a one year low of $0.61 and a one year high of $3.65. The business’s fifty day moving average price is $2.18 and its two-hundred day moving average price is $2.06.

Insider Activity

In other news, insider Paul L. Berns sold 9,819 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $3.51, for a total value of $34,464.69. Following the sale, the insider directly owned 7,395,185 shares of the company’s stock, valued at $25,957,099.35. This represents a 0.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 23,387 shares of company stock worth $82,647 in the last 90 days. 26.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NMRA. Legacy Private Trust Co. lifted its stake in shares of Neumora Therapeutics by 35.7% during the 4th quarter. Legacy Private Trust Co. now owns 19,000 shares of the company’s stock valued at $34,000 after buying an additional 5,000 shares in the last quarter. Vanguard Personalized Indexing Management LLC raised its position in Neumora Therapeutics by 10.7% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 64,429 shares of the company’s stock valued at $117,000 after purchasing an additional 6,233 shares in the last quarter. Invesco Ltd. boosted its position in Neumora Therapeutics by 6.8% during the 2nd quarter. Invesco Ltd. now owns 132,038 shares of the company’s stock valued at $97,000 after acquiring an additional 8,383 shares in the last quarter. CWM LLC boosted its stake in Neumora Therapeutics by 41.8% in the second quarter. CWM LLC now owns 35,750 shares of the company’s stock valued at $26,000 after acquiring an additional 10,537 shares in the last quarter. Finally, Virtu Financial LLC acquired a new position in shares of Neumora Therapeutics during the third quarter valued at about $31,000. Institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics News Summary

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: William Blair upgraded Neumora, raising the firm’s rating on NMRA — this analyst move drove buying interest and was reported across outlets. William Blair upgrade
• Positive Sentiment: Following the upgrade, NMRA shares gapped up and hit a new 52-week high — a technical/market reaction that can attract momentum buyers. Shares gap up / 52-week high
• Neutral Sentiment: Recent trading context: volume is below its 3-month average, market cap is roughly $581M, the shares have high short-term volatility (beta ~3.2) and the company shows strong current/quick ratios — these fundamentals provide context but aren’t a single directional catalyst.
• Negative Sentiment: Insider sale — Michael Lee Milligan sold 1,436 shares at ~$3.56 (filed 2/17). This reduced his stake by ~6.4%, which can be viewed negatively by the market. Milligan Form 4
• Negative Sentiment: Insider sale — Paul L. Berns sold 9,819 shares at ~$3.51 (filed 2/17), a small percentage reduction of a large position; notable due to size. Berns Form 4
• Negative Sentiment: Insider sale — President Joshua Pinto sold 5,967 shares at ~$3.54 (filed 2/17), a ~9.4% cut in his holdings; insider selling by an executive is often viewed unfavorably. Pinto Form 4
• Negative Sentiment: Insider sale — Daljit Singh Aurora sold 6,165 shares at ~$3.56 (filed 2/17), trimming his stake by ~6.9%; multiple contemporaneous insider sales amplify perceived negative signal. Aurora Form 4

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.